Abiopharma

🔍 Lippis Daniel J. (Executive)

Company: Edwards Lifesciences Corp (EW)

Report Date: 2026-01-09

Detailed Transactions and Holdings:

• Acquired 1,019 shares of Common Stock at $59.2567 per share (Direct)
  Date: 2026-01-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 23,020.91 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,019 shares of Common Stock at $85.7037 per share (Direct)
  Date: 2026-01-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 22,001.91 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,019 shares of Employee Stock Option (Right to Acquire) at $59.2567 per share (Derivative)
  Date: 2026-01-09 | Code: M | Expires: 2026-05-07 | Exercise: 2020-05-08 | equity_swap_involved: 0 | shares_owned_after: 4,076.00 | transaction_form_type: 4

Footnotes:

• F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.
• F2: This transaction was executed in multiple trades at prices ranging from $85.45 to $85.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of theIssuer, full information regarding the number of shares and prices at which the transaction was effected.
• REMARKS: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.